Zimmer Biomet Stock Forecast, Price & News NYSE:ZBH

Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC. You can find your newly purchased ZBH stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

To maintain its market position, Zimmer Biomet must continue to innovate and invest in research and development. Zimmer Biomet is expanding its product portfolio through innovation and acquisitions. The company has a robust pipeline of new https://g-markets.net/helpful-articles/javascript-candlestick-charts-examples/ products in development, including the Persona Revision Knee System and the ROSA Knee System. Zimmer Biomet is also pursuing strategic acquisitions to expand its presence in emerging markets and strengthen its position in existing markets.

• Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
• In early 2020, the company’s stock price experienced a sharp decline due to the COVID-19 pandemic, but since then, it has rebounded and continues to experience volatility.
• The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.
• Finally, changes in consumer preferences and healthcare trends could impact demand for Zimmer Biomet’s products.

The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. 240 employees have rated Zimmer Biomet Chief Executive Officer Bryan Hanson on Glassdoor.com.

Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2022

Zimmer Biomet issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of $7.40-$7.50 for the period, compared to the consensus estimate of $7.06. The company issued revenue guidance of $7.29 billion-$7.36 billion, compared to the consensus revenue estimate of $7.14 billion. As of June 15th, there was short interest totaling 3,810,000 shares, an increase of 27.0% from the May 31st total of 3,000,000 shares. Based on an average daily trading volume, of 1,410,000 shares, the short-interest ratio is currently 2.7 days. The company’s leadership team is led by President and CEO Bryan Hanson, who has been in his current role since 2017.

The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Fourth quarter net sales from continuing operations of $1.825 billion increased 2.7% and 8.3% on a constant currency1 basis Fourth quarter diluted loss per share from continuing operations was $0.62; …

Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC.

Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits.

One share of ZBH stock can currently be purchased for approximately $142.65. Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise. The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction. Get this delivered to your inbox, and more info about our products and services. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.

Should I buy or sell ZBH stock?

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers. Zimmer Biomet’s stock is owned by a number of retail and institutional investors. Top institutional shareholders include Centre Asset Management LLC (0.04%), Thomasville National Bank (0.04%), Brookstone Capital Management (0.02%), Jacobs & Co. CA (0.02%), DnB Asset Management AS (0.02%) and DNB Asset Management AS (0.02%). Insiders that own company stock include Arthur J Higgins, Chad F Phipps, Sang Yi and Zuilen Wilfred Van.

Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Third quarter net sales from continuing operations of $1.670 billion decreased 0.9% and increased 5.0% on a constant currency1 basis Third quarter diluted earnings per share from continuing operations…

Robert W. Baird Sticks to Their Buy Rating for Zimmer Biomet Holdings (ZBH)

New daily records for COVID-19 cases and hospitalizations mean these stocks are probably headed in opposite directions. As elective surgery candidates return to operating rooms, revenue will ramp up. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment.

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. The technique has proven to be very useful for finding positive surprises. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Here’s Why You Should Retain Teleflex (TFX) Stock for Now

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Shareholders of record on Monday, June 26th will be paid a dividend of $0.24 per share on Monday, July 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.67%. The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. Finally, changes in consumer preferences and healthcare trends could impact demand for Zimmer Biomet’s products.

The orthopedic industry is highly competitive, with a few major players dominating the market. Zimmer Biomet is one of the largest companies in the industry, with a strong presence in the joint reconstruction, spine, dental, and sports medicine markets. The industry is also highly regulated, with various regulatory bodies overseeing the safety and efficacy of medical devices. Zimmer Biomet has a track record of complying with regulatory requirements and maintaining high-quality standards. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account.

15 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Zimmer Biomet in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “hold” ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares. Additional information about your broker can be found by clicking here.

First quarter net sales of $1.831 billion increased 10.1% and 13.2% on a constant currency1 basis First quarter diluted earnings per share were $1.11; adjusted1 diluted earnings per share were $1.89 C… According to 19 analysts, the average rating for ZBH stock is “Hold.” The 12-month stock price forecast is $137.64, which is a decrease of -3.51% from the latest price. Another risk facing Zimmer Biomet is the potential for increased competition. While the company is one of the most significant players in the orthopedic industry, it faces competition from other established companies and new entrants.

Is It Time to Sell ZBH? Shares are down today.

These returns cover a period from January 1, 1988 through May 15, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.